Enanta Pharmaceuticals, Inc.(ENTA)

$14.58▲0.07 (48.24%)

Chart

Enanta Pharmaceuticals, Inc.(ENTA)

NASDAQ

$14.58▲0.07 (48.24%)

Chart Studio

ENTA(ENTA)

ENTA

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.50

Aug 10, 2026 · Reports before open

Revenue Estimate

$17M

Analyst Sentiment

Wall St. Consensus

Buy

16 analysts·Moderate coverage

Score

14 Buy (88%)0 Hold (0%)2 Sell (12%)

Rating Breakdown

Strong Buy

00%

Buy

1488%

Hold

00%

Sell

213%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$20.00

+37.2%

Consensus

$20.00

+37.2%

Bull

$20.00

+37.2%

12-Month Target Range16 analysts

$20.00$20.00$20.00

Current $14.58Consensus

Current Price

$14.58

Upside to Consensus

$5.42

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-1.62%

EPS—

FY2028

Rev+11.85%

EPS—

FY2029

Rev+27.54%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$68M	$67M	$75M	$96M	$154M
Low	$68M	$67M	$69M	$88M	$141M
High	$69M	$68M	$79M	$101M	$163M
EBITDA Avg	$-68M	$-67M	$-75M	$-96M	$-154M
Low	$-69M	$-68M	$-79M	$-101M	$-163M
High	$-68M	$-67M	$-69M	$-88M	$-141M
EBIT Avg	$-68M	$-67M	$-75M	$-96M	$-154M
Low	$-69M	$-68M	$-79M	$-101M	$-163M
High	$-68M	$-67M	$-69M	$-88M	$-141M
Net Income Avg	$-48M	$-42M	$-62M	$-38M	$-32M
Low	$-59M	$-56M	$-75M	$-41M	$-35M
High	$-38M	$-29M	$-25M	$-34M	$-29M
EPS Avg	$-2.28	$-1.97	$-1.91	$-1.78	$-1.52
Low	$-2.77	$-2.60	$-3.53	$-1.91	$-1.63
High	$-1.77	$-1.35	$-1.19	$-1.59	$-1.35
Analysts (Rev / EPS)	4 / 4	4 / 4	4 / 4	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027
Revenue Avg	$17M	$17M	$15M	$16M	$15M
Low	$16M	$15M	$14M	$14M	$13M
High	$17M	$18M	$17M	$17M	$16M
EBITDA Avg	$-17M	$-17M	$-15M	$-16M	$-15M
Low	$-17M	$-18M	$-17M	$-17M	$-16M
High	$-16M	$-15M	$-14M	$-14M	$-13M
EBIT Avg	$-17M	$-17M	$-15M	$-16M	$-15M
Low	$-17M	$-18M	$-17M	$-17M	$-16M
High	$-16M	$-15M	$-14M	$-14M	$-13M
Net Income Avg	$-14M	$-8M	$-9M	$-9M	$-10M
Low	$-21M	$-9M	$-10M	$-10M	$-12M
High	$-8M	$-7M	$-8M	$-8M	$-9M
EPS Avg	$-0.67	$-0.36	$-0.43	$-0.43	$-0.49
Low	$-0.98	$-0.41	$-0.48	$-0.49	$-0.55
High	$-0.37	$-0.32	$-0.37	$-0.38	$-0.42
Analysts (Rev / EPS)	4 / 4	3 / 2	3 / 2	2 / 1	2 / 1

Earnings Surprises

Recent Analyst Actions

Jun 23, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)

Target:$20.00

+49.6%from $13.37

Oct 1, 2025Jefferies

Enanta upgraded to Buy from Hold at Jefferies

Target:$20.00

+83.7%from $10.88

Jun 3, 2025JMP Securities

Enanta price target raised to $24 from $23 at Citizens JMP

Target:$24.00

+233.8%from $7.19

Dec 9, 2022H.C. Wainwright

HC Wainwright & Co. Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $56

Target:$56.00

+33.5%from $41.96

Nov 22, 2022RBC Capital

RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $54

Target:$54.00

+16.4%from $46.40

Jul 29, 2022Piper Sandler

Enanta's 'strong' EDP-235 data supports 'impressive' profile, says Piper Sandler

Target:$87.00

+69.7%from $51.27

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance